University of Hull logo

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomised controlled study (2019)
Journal Article
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., …Sathyapalan, T. (2019). Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomised controlled study. Clinical Endocrinology, 90(6), 805-813. https://doi.org/10.1111/cen.13968

Background: Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascu... Read More